Best Agrolife (539660) Q4 24/25 earnings summary

Executive summary

• Achieved significant operational turnaround in Q4 FY25, reducing quarterly loss from INR 92 crore to INR 20-24 crore year-over-year and returning to positive EBITDA of INR 40 million from negative INR 670 million, driven by cost optimization and strategic restructuring.

• Revenue for Q4 FY25 rose 103% year-over-year to INR 274 crore, supported by improved seasonal conditions and operational efficiency.

• Full-year consolidated revenue was INR 1,814-1,818.89 crore, slightly down from INR 1,873-1,876.48 crore, with branded sales volume up but offset by price declines in non-patented products.

• Focus remains on branded, patented products, with three to four new launches planned annually, a strong R&D pipeline, and biopesticides launch planned for FY26.

• Board approved audited financial results for FY25 with unmodified audit opinions and recommended a final dividend of INR 3 per share, subject to shareholder approval.

Financial highlights

• Gross margin improved from 24.7% to 29.5% year-over-year, reflecting a shift to higher-value branded products.

• Operating cash flow increased 40% to INR 192 crore; full-year cash flow from operations rose to INR 228 crore from INR 35 crore.

• Working capital reduced by INR 146 crore (54% improvement), inventory down by INR 185 crore (19% improvement), and total borrowing reduced by INR 161 crore (25% reduction).

• EBITDA for FY25 was INR 200 crore (11% margin), down from INR 225 crore, due to higher marketing and employee costs.

• Standalone net profit for FY25 was INR 44.47 crore, consolidated net profit was INR 69.89 crore, both impacted by subsidiary performance and tax matters.

Outlook and guidance

• Management targets EBITDA margin improvement to 15-18% in FY26, with a focus on profitability, gross margin, and cash flow rather than top-line growth.

• No specific revenue growth guidance, but expects INR 150 crore additional revenue from three new patented products in FY26.

• Anticipates substantial reduction in sales returns (previously 17-18%) through new sales policies and better demand planning.

• Brownfield expansion of INR 90 crore to be completed in 10-12 months, with revenue and EBITDA impact expected from FY27.

• Biopesticides launch and further R&D expansion planned for FY26.